Therapeutic compositions

A compound, hydroxybutyric acid technology, used in drug combinations, food ingredients containing organic compounds, food science, etc., can solve problems such as hypertriglyceridemia, increased vascular disease, pancreatic disease, and reduced leucine oxidation

Inactive Publication Date: 2004-12-08
BRITISH TECH GRP LTD
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Fourth, the consumption of large amounts of lipid substances in adults can lead to severe hypertriglyceridemia, the pathological consequence of which is an increased risk of vascular disease, sporadic liver disease, and pancreatic disease, so lipids cannot be prescribed in the medical field use
It was found to be non-toxic and reduced the concentration of glucose free fatty acids and glycerol, but had no effect on reducing the oxidation of leucine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic compositions
  • Therapeutic compositions
  • Therapeutic compositions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0166] Preparation of (R)-3-hydroxybutyric acid (D-β-hydroxybutyric acid) oligomer

[0167] (R)-3-Hydroxybutyric acid (Fluka-5.0 g: 0.048 mol), p-toluenesulfonic acid (0.025 g) and benzene (100 ml) were stirred at reflux in a Dean-Stark trap apparatus for 24 hours. The reaction mixture was cooled and the benzene was distilled off in vacuo (0.5 mmHg). 4.4 g of a colorless oil were obtained and a 20 mg sample was taken to convert to its methyl ester for NMR determination of the number of repeating monomers. These experiments showed that the product was a mixture of D-β-hydroxybutyric acid oligomers with an average number of repeating units of 3.75, mainly a mixture of trimers, tetramers and pentamers, with tetramers being the most abundant. The product mixture can be dissolved in 1 N sodium hydroxide solution.

Embodiment 2

[0169] Preparation of acetoacetyl esters of (R)-3-hydroxybutyric acid oligomers

[0170] Another batch of the colorless oil from Example 1 (4.5g) was heated with diketene (3.8g) and sodium acetate (0.045g) at 60°C for 1 hour under nitrogen flow. Some more diketene (3.8g) was added and the reaction was heated for an additional hour, cooled, diluted with ether, washed with water and extracted with saturated sodium bicarbonate (5 x 100ml). The extracts were combined, washed with ether, and then acidified (dropped) with concentrated hydrochloric acid. Extraction with ethyl acetate (3 x 50ml) followed by drying over magnesium sulphate and evaporation in vacuo. A yellow solid / oil mixture (7.6 g) was obtained which was chromatographed on a silica column eluting with dichloromethane / methanol (98:2) to give the product as a bright amber oil. Isolate the faster impurity (1.6g) of flow velocity, it walks the separation column once more with carbon tetrachloride / methanol (99: 1), reclai...

Embodiment 3

[0172] Oral administration of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate, and acetoacetyl D-β-hydroxybutyrate oligomers to rats

[0173] The ability of oral administration of D-β-hydroxybutyric acid and the oligomers of Examples 1 and 2 to increase blood ketone body levels was investigated in the following manner. Rats were fasted overnight and then gavaged with 4M D-[beta]-hydroxybutyrate adjusted to pH 7.74 with methylglucamine at a dose of 100 [mu]l / 100 g body weight. Use of NAD in Anal. Biochem. 131, p478-482 (1983) + / EDTA analysis method to measure the level of D-β-hydroxybutyric acid in the blood. 1.0ml of a solution prepared with 2-amino-2-methylpropanol (100mM pH 9.9, 0.094g / 10ml), NAD+ (30mM, 0.199g / 10ml) and EDTA (4mM, 0.015g / 10ml), and 4 μl of sample or D-β-hydroxybutyrate control was added to each cuvette.

[0174]Because the rats had been fasted for a period of time, initial levels of D-beta-hydroxybutyrate were already elevated compared to the fed ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Compositions containing ketone bodies and / or metabolic precursors thereof suitable for administration to humans and animals, which are characterized by (i) enhancing cardiac performance, especially the efficiency of the heart in utilizing glucose, (ii) providing energy, especially is to provide energy in diabetes and insulin resistance, (iii) to treat conditions caused by brain cell damage, especially by delaying or preventing brain damage in memory-related areas of the brain, such as in Alzheimer's disease and Brain damage found in brains with similar conditions. These compositions can be used as nutritional supplements, for example for athletes, or for the treatment of diseases, especially disorders related to cardiac insufficiency, insulin resistance and neuronal damage. The invention also provides methods of treatment as well as novel esters and polymers for inclusion in the compositions of the invention.

Description

[0001] This application is a divisional application of a Chinese patent application with a priority date of March 17, 1997, an application date of March 17, 1998, and application number 98805163.X. technical field [0002] The present invention relates to compositions suitable for administration to humans and animals, characterized in particular by (i) enhancing cardiac performance, especially the efficiency with which the heart utilizes glucose, (ii) providing energy, especially in diabetes and insulin resistance (iii) treating conditions caused by damage to brain cells, especially by delaying or preventing brain damage in areas of the brain associated with memory, such as in the brain in Alzheimer's disease and similar conditions Find the brain damage, to achieve therapeutic effect. These compositions can be used as nutritional supplements, for example for athletes, or for the treatment of phlegm disorders, especially those associated with cardiac insuff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61P3/10A23L1/30A23L33/00A61K31/121A61K31/19A61K31/22A61K31/765A61P9/00A61P25/00A61P25/08A61P43/00C07C59/10C08G63/06
CPCA23V2002/00A61K31/765C08G63/06A23L1/30A61K31/22A23L1/293A23L33/10A23L33/30A61P3/00A61P3/10A61P5/50A61P9/00A61P25/00A61P25/02A61P25/08A61P25/16A61P25/28A61P43/00A23V2250/30A61K31/19
Inventor R·L·韦奇
Owner BRITISH TECH GRP LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap